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Aims and organization of the network
he German Research Network On
Schizophrenia (GRNS) is one of 17 existing medical
research networks funded by the German Federal
Ministry of Education and Research (BMBF) since 1999
in order to improve care of patients with illnesses char-
acterized by high morbidity and/or mortality. Each of
these networks is funded for a maximum of 8 years,with
up to 2.5 million Euro per year during the first 5 years
and up to 0.5 million Euro per year for the last 3 years.
Additional sponsoring (about 5% of the budget) by the
industry is provided for research projects or public rela-
tions activities of the network.One of the main reasons
that the BMBF established such networks originates
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The German Research Network On Schizophrenia (GRNS)
is a nationwide network currently comprising 16 psychi-
atric university departments and 14 state and district
hospitals, as well as six local networks of psychiatric prac-
tices and general practitioners collaborating on about
25 interrelated, multicenter projects on schizophrenia
research. The GRNS aims to intensify collaboration and
knowledge exchange between leading research institu-
tions and qualified routine care facilities, both within
(horizontal network) and between (vertical network) the
two levels of research and care, in order to create the sci-
entific preconditions for optimization of the manage-
ment of schizophrenia. The concept and the first results
of studies aiming at the investigation of (i) strategies for
early detection and early intervention in the prodromal
stage of psychosis; (ii) treatment in first-episode schizo-
phrenia; (iii) quality management; and (iv) destigmati-
zation, are described as examples of this effort.       
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insufficiently transferred to practice, and problems in
everyday care worth being scientifically investigated are
only insufficiently recognized by researchers.
Thus, the structural aim of the GRNS–in a way to be
taken as a precondition–consists of the establishment of
long-term communication structures between research,
services,consumers,and the public.A means for attain-
ing these aims is the creation or expansion,intensified
utilization,and routine application of collaboration and
knowledge exchange within (horizontal networking) and
between (vertical networking) the two levels of research
and care. With regard to the funding by the Federal
Ministry of Research,the framework for attaining these
objectives is that of research projects,which constitute
the means for intensified collaboration between institu-
tions and optimized care for patients with schizophrenia.
The network comprises about 25 interrelated research
studies and projects on health care education with high
practice relevance.A current total of 16 psychiatric uni-
versity departments and 14 state and district hospitals,as
well as six local networks of psychiatric practices and
general practitioners throughout Germany,participate in
these studies.
As regards content,the major objective of the GRNS is
to create the scientific preconditions for the implemen-
tation of strategies for early detection and early inter-
vention in the prodromal stage of the first episode
(“Project Network I”),for the optimization of acute and
long-term treatment in first-episode patients and for the
rehabilitation in patients with residual symptoms
(“Project Network II”).Quality of care in hospitals and
practices is evaluated and improved by quality assurance
programs implementing the existing guidelines for out-
and inpatient treatment.Basic research on structural and
functional brain imaging and genetic markers investi-
gates underlying determinants of the manifestation and
re-manifestation of the illness as well as the individual
response to drug treatment (“Special Network”on mol-
ecular and pharmacogenetics).A number of more gen-
eral projects on fighting stigma and discrimination,health
care economy,postgraduate training,quality assurance,
and methodology complete the spectrum of network pro-
jects (see ref 1 and www.kompetenznetz-schizophre-
nie.de for more information).Generally,the studies are
multicenter studies designed in such a manner that ver-
tical and horizontal networking is forced,essential,or at
least supported. In order to create synergy and added
value as important criteria for successful networking,
most of the projects are strongly interrelated regarding
conceptual background,method,and organization.
The superordinate aim of these studies is to allow for an
improvement of the course and the outcome of schizo-
phrenia along with considering cost-benefit aspects.
Examples of these studies will be given in subsequent
sections.Since some of the studies are long-term studies
which finished recruitment only recently,reliable results
will only be available later in 2006.Thus,the description
will mainly focus on the concept of the studies with
regard to the improvement of the management of schiz-
ophrenia.
Example I: early intervention in persons 
at risk of schizophrenia
It is known that the first treatment contact of people suf-
fering from schizophrenia is preceded by a period of
manifest psychotic symptoms, on average lasting for 1
year, and a prepsychotic prodromal period of about 5
years with increasing negative and unspecific symptoms
and functional impairment.
2At the same time,it has been
shown that a delayed treatment is associated with signif-
icant disadvantages for schizophrenia patients, often
resulting in functional and social decline.
3-6Thus,in order
to optimize outcome it seems essential to recognize and
treat at-risk persons and schizophrenia patients as early
as possible. For this purpose awareness programs are
being carried out as a first step in several German cities
within the GRNS, in order to improve utilization of
newly founded early-recognition centers by at-risk per-
sons.As a second step,two early recognition and inter-
vention studies are carried out; these are also used to
prospectively validate a two-step early-recognition inven-
tory (ERI) and a set of cognitive tests developed for
early detection of at-risk persons.
7
For the two early intervention studies,two groups of at-
risk persons are selected from the larger group of persons
referred to the early-recognition centers, according to
their presumed prodromal stage.Based on previous lon-
gitudinal observations,an “early initial prodromal stage”
is assumed in case subjects report predictive basic symp-
toms in the ERI
8 or in case they have a first-degree rela-
tive with schizophrenia and show a marked decline in
global functioning.“Late initial prodromal stages” are
defined by the occurrence of brief limited intermittent
psychotic symptoms (BLIPS) or by attenuated positive
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dromal state are included into an early intervention study
examining the effects of a newly developed cognitive-
behavioral therapy (CBT) strategy for prodromal per-
sons,which is compared with clinical management within
a randomized control design over a 24-month period.
9,10
Persons in the late prodromal state of psychosis are
included into a second early intervention study, which
compares the effects of atypical antipsychotic medication
with amisulpride in combination with clinical manage-
ment (supported by crisis intervention or family coun-
seling in case of need,but no regular psychotherapy) to
such clinical management alone.
11 This is a phase-III
study with an open-label, randomized parallel design,
with a treatment period of 2 years.Effects of both stud-
ies will be evaluated with regard to improvement of pro-
dromal symptoms,prevention of social decline,and sup-
pression,or at least delay,of progression to psychosis.
Preliminary results of both studies are encouraging,indi-
cating a benefit for at-risk persons treated with CBT or
amisulpride, respectively, compared with the control
treatments with regard to these outcome variables.
Should these trends be validated in the final analyses,the
use of early recognition and early intervention strategies
as developed within the GRNS would be an important
step in the management of developing psychosis.
Example II: acute and long-term treatment 
in first-episode schizophrenia
Though a number of studies have shown advantages of
“atypical”second-generation antipsychotics compared
with conventional antipsychotics in acute treatment (for
review see ref 12) as well as in long-term treatment of
schizophrenia (for review see ref 13) it is still under
debate whether these results may be biased by the high
dosages of conventional antipsychotics usually used in
these studies.
14,15 Low-potency neuroleptics even might
not induce more extrapyramidal side effects under a low-
dose strategy than second-generation drugs
16 and the
potential advantage of atypical antipsychotics may be
compromised by their side effects, such as weight gain
and metabolic effects.
17 Nevertheless, atypical antipsy-
chotics are recommended as first-choice treatment for
both first- and multiple-episode schizophrenia
18-19 or for
first-episode schizophrenia preferentially.
20 However,
independent long-term studies in first-episode patients
substantiating these recommendations are lacking
21-22 or
are still under way, such as the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) trial in the
US
23 and the EUropean First Episode Schizophrenia
Trial (EUFEST) study in Europe;
24 Beyond this uncer-
tainty regarding the best kind of antipsychotic treatment
for the special group of first-episode patients, it is fur-
thermore unclear how long treatment should be contin-
ued after cessation of the first acute phase.
25-26 Published
guidelines recommend treatment durations of minimum
1 year;
27-28 the appropriate duration of further treatment
in case of symptom remission, however, has not been
adequately specified.
In order to contribute to these open questions, a com-
prehensive acute and long-term treatment study in
patients with first-episode schizophrenia is currently been
conducted in up to 13 German university hospitals within
the GRNS.
29The study comprises a prospective double-
blind,randomized,parallel-group comparison of risperi-
done as a new-generation antipsychotic with haloperidol
as a conventional antipsychotic.Both drugs are adminis-
tered in rather low daily dosages of 2 to 8 mg per day
during the 8 weeks of acute treatment,and thereafter in
a reduced dosage–where possible–of 2 to 4 mg per day
during a 2-year long-term treatment period.To investi-
gate the necessary duration of long-term treatment in
first-episode patients,patients completing the first treat-
ment year without relapse are randomly allocated to
either maintenance treatment or stepwise drug discon-
tinuation in the second treatment year. In case of
impending re-exacerbations,prodrome-based early inter-
vention,either by means of resumption or augmentation
of neuroleptic treatment (depending on the basic treat-
ment strategy of discontinuation or maintenance treat-
ment) or by means of treatment/additional treatment
with the benzodiazepine lorazepam is applied in the sec-
ond treatment year to prevent relapses.This randomized,
double-blind comparison shall contribute to the open
question of whether prodromes are unspecific conse-
quences of stress experience, treatable with benzodi-
azepines,or have to be regarded as more specific,prepsy-
chotic symptoms requiring neuroleptic treatment.
30
Preliminary findings so far suggest that the treatment
with low dosages of antipsychotics is feasible and effec-
tive,and leads to a significant improvement in positive,
negative,and prodromal symptoms in first-episode schiz-
ophrenia patients.None of the patients has fulfilled the
criteria for relapse within the first year of treatment.
Because the medication is only about to be unblinded,
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between both drugs is not yet available.
Example III: remediation of 
social cognitive impairments
Schizophrenia patients often exhibit impairments in
facial affect recognition (see ref 31 for review),which is
already present in first-episode patients,
32 and even in
unaffected siblings of schizophrenia patients.
33 Such
impairments are strongly associated with more global
social dysfunctions characteristic of schizophrenia
34-35 and
may have adverse effects on psychosocial functioning
independent of the presence and severity of positive and
negative symptoms and cognitive deficits.
36Thus,these
impairments represent a core feature of the disorder and
are of high relevance for the psychosocial functioning of
the patients.The traditional drug and psychological treat-
ment usually administered to schizophrenia patients
seem to be ineffective in this regard,as indicated by the
stability of the impairment across different stages of the
disorder despite treatment.
37Against this background,a
new training program for the remediation of such impair-
ments has been developed within the GRNS.The effects
of this “Training of Affect Recognition” (TAR)
38 have
been compared with a cognitive remediation program
(CRT) primarily aiming at improving attention,memory,
and executive functioning,and with treatment as usual
(TAU) without participation in a specific remediation
program within a randomized three-group pre-post
design.
39 Results indicated that patients on TAR signifi-
cantly improved in facial affect recognition,with recog-
nition performance after training approaching the level
of healthy controls from former studies.Patients on CRT
and those without special training (TAU) did not
improve in affect recognition,though patients on CRT
improved in verbal memory functions. According to
these results,remediation of disturbed facial affect recog-
nition in schizophrenia patients is possible, but not
achievable with a traditional cognitive rehabilitation pro-
gram such as the CRT. Instead, functional specialized
remediation programs such as the newly developed TAR
are a more suitable option. Whether these promising
training effects of the TAR endure across time and per-
vade into everyday social functioning has to be investi-
gated by future studies.If these effects can be validated,
such training programs could become an important mod-
ule of psychosocial rehabilitation programs in future.
Example IV: quality management 
in routine care facilities
Optimizing treatment of schizophrenia through imple-
mentation of guidelines is essential for early and acute as
well as long-term and chronic phases of schizophrenia.
Such measures of quality assurance shall guarantee opti-
mal care in accordance with the state-of-the-art knowledge
under consideration of available resources.At present it is
estimated that only 40% to 50% of schizophrenia patients
are treated according to scientific standards and treatment
guidelines.
40-41Although several treatment guidelines for
schizophrenia have been published in recent years,it has
been supposed that only a case-focused implementation
of these guidelines will lead to an improvement in out-
come quality measures.
42
Therefore,two projects targeting quality assurance,either
in inpatient care or in outpatient care, have been per-
formed within the GRNS.The first of these projects tar-
geted the systematic development,implementation,and
evaluation of specific measures of quality management
in inpatient treatment of 597 schizophrenia patients at
seven psychiatric hospitals, mostly district hospitals.
43
Using an experimental control group design with pre-
and post-assessments,quality-orientated interventions
according to the concept of Total Quality Management
(TQM) and with reference to the German treatment
guidelines
28 were compared in four experimental hospi-
tals with documentation of structural parameters (hos-
pital and patient characteristics), of treatment, and of
outcome in three control hospitals.Experimental hospi-
tals received feedback by means of comparative bench-
marking,and were guided in implementing quality circles
for specific problem areas identified from the bench-
marking process.Results indicated that poorer average
clinical outcome was associated with lower guideline con-
formity in a variety of treatment domains.After case-mix
adjustment,benchmarking proved to be an opportunity
to improve quality of treatment and promote guideline
conformity.
The second project followed a similar approach for opti-
mizing outpatient treatment of schizophrenia.The main
focus was to implement guidelines, but also other ele-
ments of internal (documentation system,monitoring)
and external (benchmarking) quality management in
four hospital-associated networks of private psychiatric
practices in three different German cities (Düsseldorf,
Freiburg,and Munich).One of the three experimental
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with implemented treatment guidelines and decision-
support,and received comparative benchmarking.
44This
computerized documentation system draws the attention
of the physician to the treatment guidelines by means of
a pop-up window showing the relevant guideline algo-
rithm whenever the entered data indicate critical changes
in the patient’s clinical status.Two further experimental
groups used either the computer-based documentation
system without implemented guidelines and bench-
marking,or paper-and-pencil documentation with addi-
tional organization in quality circles. A control group
used paper-and-pencil documentation without additional
organization in quality circles.
Results in 583 patients with schizophrenia treated by 55
psychiatrists for at least 16 months demonstrated a sig-
nificantly better outcome in patients in the experimental
practices, either using the decision support system or
working with quality circles, as compared with those
practices merely documenting their treatment, either
computer-based or with paper and pencil, but without
further measures of quality assurance.
Example V: reduction of stigmatization of
people with schizophrenia
The stigma associated with mental illness and psychiatric
treatment, and the discrimination toward people with
mental illnesses that frequently results from this,are the
main obstacles preventing early and successful treatment.
To reduce such stigma and discrimination, especially
towards people with schizophrenia,the World Psychiatric
Association's (WPA) global anti-stigma program
"Fighting Stigma and Discrimination because of
Schizophrenia - Open the Doors"
45 is currently being
implemented in 27 countries.Since August 1999,the cam-
paign has also been carried out in seven cities in
Germany,partly within,and with funding of,the GRNS.
46
A survey of attitudes towards people with mental illness
was conducted at the beginning of this campaign in 7246
persons in six German cities by telephone using a stan-
dardized questionnaire.
47 The respondents were asked
about their knowledge with regard to schizophrenia,their
social distance from people with schizophrenia,and esti-
mations of the social stigmatization of mental patients in
general. Thereafter public information programs and
educative measures aimed at selected target groups were
performed,and the opportunity for personal contact with
mentally ill people was promoted in two of the cities in
order to improve the public's knowledge regarding symp-
tomatology, causes, and treatment options for schizo-
phrenia.The first results of a recently executed second
survey of the same persons indicate that such improve-
ment could indeed be partly obtained in these two cities,
whereas no comparable changes occurred in the cities
not participating in the antistigma campaign.The next
step to be performed is to investigate whether improved
knowledge in turn also contributes to abolishing preju-
dice and negative perceptions and facilitates the social
reintegration of those suffering from mental illness.
Perspectives
The GRNS has now been funded for about 6 years.
During this period,significant structural improvements
regarding intensified collaboration between and within
the research and care levels have already been achieved.
Moreover, significant contributions to improved man-
agement of schizophrenia have already been obtained,
for instance in the area of quality assurance in inpatient
and outpatient treatment.Several studies regarding early
detection and early intervention,as well as treatment of
first-episode schizophrenia, were initially designed as
long-term studies lasting up to 5 years, which only
recently reached the phase of analysis.Due to the com-
prehensive design of these carefully coordinated studies
targeting a number of important and open questions in
schizophrenia,significant results and surplus effects can
be expected for the coming months.The next essential
task will be to transfer these results into health care.
Based on a successful midterm evaluation,further fund-
ing has recently been granted by the BMBF until mid-
2008 in order to promote this transfer process. Thus,
development and implementation of measures for early
recognition and intervention, for treatment of first-
episode schizophrenia,for quality management,and for
destigmatization will be in the focus of this last funding
period before the GRNS has to finance itself by other
resources.These measures will comprise development of
manuals and brochures,and continued medical educa-
tion measures,as well as the setting up of special compe-
tence centers for each of these topics.Nevertheless,an
ongoing aim of the GRNS will still be to offer a research
platform,particularly for clinical studies,in order to con-
tinue successful horizontal networking between the insti-
tutes of research.Maintenance and extension of the exist-
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119ing DNA and clinical data banks will be an important
part of this effort.The complexity of psychiatric disorders
on the one hand, and the progressive specialization in
research,especially when using complex biological meth-
ods,on the other hand,results in an increasing necessity
for inter- and intradisciplinary collaboration organized
into larger networks like the GRNS. Primarily, such a
strategy seems promising to find answers to the urgent
and complex questions regarding schizophrenia that are
still unresolved. ❏
This manuscript was written within the framework of the German Research
Network on Schizophrenia, which is funded by the German Federal Ministry
for Education and Research BMBF (grants 01GI9932, 01GI0232, 01GI0532).
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La red de investigación alemana sobre 
la esquizofrenia y su repercusión en el 
tratamiento
La Red de Investigación Alemana sobre la
Esquizofrenia (GRNS), de ámbito nacional, abarca
en este momento 16 servicios universitarios de psi-
quiatría y 14 hospitales estatales y de distrito, así
como seis redes locales de consultas de psiquiatría
y medicina general que colaboran en cerca de 25
proyectos multicéntricos interrelacionados sobre el
estudio de la esquizofrenia. La GRNS pretende
intensificar la colaboración y el intercambio de
conocimientos entre instituciones científicas de pri-
mer orden y establecimientos cualificados de aten-
ción sanitaria, tanto dentro (red horizontal) como
entre (red vertical) los dos niveles de investigación
y asistencia, a fin de crear las condiciones científicas
previas para optimar el tratamiento de la esquizo-
frenia. Como ejemplos de esta iniciativa se descri-
ben el concepto y los resultados preliminares de los
estudios para la investigación de (i) estrategias para
la detección e intervención precoz en el estadio
prodrómico de la psicosis; (ii) tratamiento del pri-
mer episodio de esquizofrenia; (iii) gestión de la
calidad; e (iv) eliminación de los estigmas. 
Le réseau de recherche allemand concernant
l’impact de la schizophrénie sur sa prise en
charge
Le réseau de recherche allemand sur la schizophré-
nie (GRAS) est un réseau international comprenant
actuellement 16 services universitaires de psychia-
trie et 14 hôpitaux régionaux et d’états, ainsi que
six réseaux locaux de psychiatres et de médecins
généralistes travaillant ensemble sur environ 25
projets multicentriques et corrélés concernant la
recherche sur la schizophrénie. Le but du GRAS est
d’intensifier les échanges de connaissance et de
collaboration entre les établissements de recherche
de premier plan et les structures qualifiées de soins
courants, à la fois à l’intérieur (réseau horizontal)
et entre (réseau vertical) les deux niveaux de recher-
che et de soins, dans le but de créer les conditions
scientifiques initiales pour optimiser la prise en
charge de la schizophrénie. Voici comme exemples
de cet effort le concept et les premiers résultats
visant la recherche 1) de stratégies pour une détec-
tion et une intervention précoces au stade des pro-
dromes de la psychose ; 2) un traitement du pre-
mier épisode de la schizophrénie ; 3) une prise en
charge de qualité ; et 4) une déstigmatisation.
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